Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 721

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category

Open access
Luger, Dror, Silver, Phyllis B., Tang, Jun, Cua, Daniel, Chen, Zoe, Iwakura, Yoichiro, Bowman, Edward P., Sgambellone, Nicole M., Chan, Chi-Chao, Caspi, Rachel R.·2008·The Journal of Experimental Medicine
DOI 10.1084/jem.20071258
Open this paper in CoChat — free account

Abstract

Experimental autoimmune uveitis (EAU) represents autoimmune uveitis in humans. We examined the role of the interleukin (IL)-23–IL-17 and IL-12–T helper cell (Th)1 pathways in the pathogenesis of EAU. IL–23 but not IL-12 was necessary to elicit disease by immunization with the retinal antigen (Ag) interphotoreceptor retinoid-binding protein (IRBP) in complete Freund's adjuvant. IL-17 played a dominant role in this model; its neutralization prevented or reversed disease, and Th17 effector cells induced EAU in the absence of interferon (IFN)-γ. In a transfer model, however, a polarized Th1 line could induce severe EAU independently of host IL-17. Furthermore, induction of EAU with IRBP-pulsed mature dendritic cells required generation of an IFN-γ–producing effector response, and an IL-17 response by itself was insufficient to elicit pathology. Finally, genetic deficiency of IL-17 did not abrogate EAU susceptibility. Thus, autoimmune pathology can develop in the context of either a Th17 or a Th1 effector response depending on the model. The data suggest that the dominant effector phenotype may be determined at least in part by conditions present during initial exposure to Ag, including the quality/quantity of Toll-like receptor stimulation and/or type of Ag-presenting cells. These data also raise the possibility that the nonredundant requirement for IL-23 in EAU may extend beyond its role in promoting the Th17 effector response and help provide a balance in the current Th1 versus Th17 paradigm.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20071258

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 44

  1. 2000, Immunity., 13, 715, 10.1016/S1074-7613(00)00070-4 · DOI · Paper page
  2. 1986, J. Immunol., 136, 2875, 10.4049/jimmunol.136.8.2875 · doi:10.4049/jimmunol.136.8.2875
  3. 1986, J. Immunol., 136, 928, 10.4049/jimmunol.136.3.928 · DOI · Paper page
  4. 1985, Invest. Ophthalmol. Vis. Sci., 26, 1
  5. 2004, Methods Mol. Med., 102, 395
  6. 1989, J. Exp. Med., 169, 1947, 10.1084/jem.169.6.1947 · DOI
  7. 1996, J. Immunol., 156, 1654, 10.4049/jimmunol.156.4.1654 · DOI
  8. 2002, Int. Rev. Immunol., 21, 197, 10.1080/08830180212063 · DOI
  9. 1998, J. Immunol., 161, 122, 10.4049/jimmunol.161.1.122 · doi:10.4049/jimmunol.161.1.122
  10. 1994, J. Immunol., 152, 890, 10.4049/jimmunol.152.2.890 · DOI
  11. 1997, J. Immunol., 158, 5997, 10.4049/jimmunol.158.12.5997 · DOI · Paper page
  12. 1999, J. Exp. Med., 189, 219, 10.1084/jem.189.2.219 · DOI · Paper page
  13. 2002, J. Clin. Invest., 110, 493, 10.1172/JCI0215751 · DOI · Paper page
  14. 2002, J. Immunol., 169, 7104, 10.4049/jimmunol.169.12.7104 · DOI · Paper page
  15. 1997, J. Clin. Immunol., 17, 366, 10.1023/A:1027360106635 · DOI
  16. 2006, Cell Res., 16, 902, 10.1038/sj.cr.7310106 · DOI · Paper page
  17. 2006, J. Immunol., 177, 3635, 10.4049/jimmunol.177.6.3635 · DOI
  18. 2007, J. Immunol., 178, 5578, 10.4049/jimmunol.178.9.5578 · DOI
  19. 2002, Immunity., 17, 375, 10.1016/S1074-7613(02)00391-6 · DOI · Paper page
  20. 1998, Clin. Immunol. Immunopathol., 88, 4, 10.1006/clin.1998.4540 · DOI
  21. 1997, Cell. Immunol., 178, 69, 10.1006/cimm.1997.1121 · DOI
  22. 2006, Trends Immunol., 27, 17, 10.1016/j.it.2005.10.003 · DOI · Paper page
  23. 2003, J. Immunol., 170, 2153, 10.4049/jimmunol.170.4.2153 · DOI · Paper page
  24. 2003, J. Biol. Chem., 278, 1910, 10.1074/jbc.M207577200 · DOI · Paper page
  25. 2004, J. Neuroimmunol., 156, 123, 10.1016/j.jneuroim.2004.07.019 · DOI
  26. 2005, Biochem. Biophys. Res. Commun., 338, 20, 10.1016/j.bbrc.2005.08.232 · DOI
  27. 2005, Nat. Immunol., 6, 1245, 10.1038/ni1271 · DOI · Paper page
  28. 2007, Brief. Funct. Genomics Proteomics., 6, 91, 10.1093/bfgp/elm008 · DOI · Paper page
  29. 2003, Proc. Natl. Acad. Sci. USA., 100, 5986, 10.1073/pnas.1035999100 · DOI · Paper page
  30. 2006, J. Clin. Invest., 116, 1310, 10.1172/JCI21404 · DOI · Paper page
  31. 2006, Inflamm. Bowel Dis., 12, 382, 10.1097/01.MIB.0000218764.06959.91 · DOI · Paper page
  32. 2006, Immunity., 25, 309, 10.1016/j.immuni.2006.05.017 · DOI · Paper page
  33. 2006, J. Immunol., 176, 1908, 10.4049/jimmunol.176.3.1908 · DOI · Paper page
  34. 2006, J. Exp. Med., 203, 2485, 10.1084/jem.20061082 · DOI · Paper page
  35. 2006, Infect. Immun., 74, 557, 10.1128/IAI.74.1.557-565.2006 · DOI
  36. 2000, J. Immunol., 164, 670, 10.4049/jimmunol.164.2.670 · DOI · Paper page
  37. 2006, J. Clin. Invest., 116, 1317, 10.1172/JCI25308 · DOI · Paper page
  38. 2006, Invest. Ophthalmol. Vis. Sci., 47, 652, 10.1167/iovs.05-0789 · doi:10.1167/iovs.05-0789
  39. 1991, Photochem. Photobiol., 54, 1057, 10.1111/j.1751-1097.1991.tb02129.x · DOI
  40. 2006, J. Exp. Med., 203, 851, 10.1084/jem.20050429 · DOI
  41. 1990, J. Autoimmun., 3, 247, 10.1016/0896-8411(90)90144-H · DOI · Paper page
  42. 2000, Invest. Ophthalmol. Vis. Sci., 41, 127
  43. 2001, Biotechniques., 31, 186, 10.2144/01311dd03 · DOI · Paper page
  44. 1995, Invest. Ophthalmol. Vis. Sci., 36, 946

Cited by

See all 721

Metadata

Authors
Luger, D., Silver, P. B., Tang, J., Cua, D., Chen, Z., Iwakura, Y., Bowman, E. P., Sgambellone, N. M., Chan, C.-C., & Caspi, R. R.
Venue
The Journal of Experimental Medicine
Publisher
Rockefeller University Press
Published
2008-04-07
Volume
205
Issue
4
Pages
799-810
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
DOI
10.1084/jem.20071258
OpenAlex
W2104040734
Cited by
721
References
9
FWCI
72.22
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. https://app.cochat.ai/papers/10.1084/jem.20071258
The paper
Luger, D., Silver, P. B., Tang, J., Cua, D., Chen, Z., Iwakura, Y., Bowman, E. P., Sgambellone, N. M., Chan, C.-C., & Caspi, R. R. (2008). Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. The Journal of Experimental Medicine. https://doi.org/10.1084/jem.20071258

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.